{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:42:51Z","timestamp":1784547771739,"version":"3.55.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["302,689\/2020\\u20136"],"award-info":[{"award-number":["302,689\/2020\\u20136"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2024\/05739-6"],"award-info":[{"award-number":["2024\/05739-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2023\/05739-6"],"award-info":[{"award-number":["2023\/05739-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bioorg.2025.109123","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:54:44Z","timestamp":1761843284000},"page":"109123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting nitroreductases for selective drug activation: therapeutic perspectives in neglected diseases and tuberculosis"],"prefix":"10.1016","volume":"167","author":[{"given":"Isabelle Garbin","family":"Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Dotalli","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La\u00eds Yukari Sposati","family":"Matuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela Souza Tada","family":"da Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Lu\u00edsa Rodriguez","family":"Gini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Em\u00edlio Em\u00edlio","family":"Jo\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Leandro","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cau\u00ea Benito","family":"Scarim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109123_bb0005","article-title":"What constitutes a neglected tropical disease?","volume":"14","author":"Hotez","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.bioorg.2025.109123_bb0010","author":"World Health Organization (WHO), Neglected tropical diseases (NTDs)"},{"key":"10.1016\/j.bioorg.2025.109123_bb0015","article-title":"Neglected tropical diseases and the sustainable development goals: an urgent call for action from the front line, BMJ glob","volume":"4","author":"Addisu","year":"2019","journal-title":"Health"},{"key":"10.1016\/j.bioorg.2025.109123_bb0020","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S2214-109X(13)70078-0","article-title":"The drug and vaccine landscape for neglected diseases (2000\u221211): a systematic assessment","volume":"1","author":"Pedrique","year":"2013","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.bioorg.2025.109123_bb0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40249-018-0444-1","article-title":"Innovation in neglected tropical disease drug discovery and development","volume":"7","author":"Weng","year":"2018","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.bioorg.2025.109123_bb0030","author":"M\u00e9decins Sans Fronti\u00e8res, Millions of Patients Still Waiting for Medical \u201cBreakthroughs\u201d Against Neglected Diseases | M\u00e9decins Sans Fronti\u00e8res Access Campaign, M\u00e9decins Sans Fronti\u00e8res"},{"key":"10.1016\/j.bioorg.2025.109123_bb0035","unstructured":"Policy Cures Research, Global Inflation Threatens Progress on Neglected Disease Innovation despite Increase in Private Sector Funding, Sydney, 2023. https:\/\/cdn.impactglobalhealth.org\/media\/Press-Release-2023-Neglected-Disease-G-FINDER-report.pdf (accessed April 19, 2025)."},{"key":"10.1016\/j.bioorg.2025.109123_bb0040","unstructured":"World Health Organization (WHO), Ending the Neglect to Attain the Sustainable Development Goals: A Rationale for Continued Investment in Tackling Neglected Tropical Diseases 2021-2030, World Health Organization (WHO) (2022). https:\/\/www.who.int\/publications\/i\/item\/9789240052932 (accessed April 19, 2025)."},{"key":"10.1016\/j.bioorg.2025.109123_bb0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.inhe.2010.04.002","article-title":"The role of product development partnerships in research and development for neglected diseases","volume":"2","author":"Moran","year":"2010","journal-title":"Int. Health"},{"key":"10.1016\/j.bioorg.2025.109123_bb0050","unstructured":"PATH, Keeping the promise: product development partnerships' role in the new age of Health Research and product development, PATH (2021). https:\/\/www.path.org\/our-impact\/resources\/keeping-the-promise-product-development-partnerships-role-in-the-new-age-of-health-research-and-product-development\/ (accessed April 20, 2025)."},{"key":"10.1016\/j.bioorg.2025.109123_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/haschl\/qxad088","article-title":"Enabling product development partnerships to bring forward the next generation of health technologies","volume":"2","author":"So","year":"2024","journal-title":"Health Affairs Scholar"},{"key":"10.1016\/j.bioorg.2025.109123_bb0060","unstructured":"G-FINDER data portal, Impact Global Health, G-FINDER Data Portal (2024). https:\/\/gfinderdata.impactglobalhealth.org\/ (accessed April 19, 2025)."},{"key":"10.1016\/j.bioorg.2025.109123_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k1182","article-title":"Funding innovation in neglected diseases","author":"Yamey","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.bioorg.2025.109123_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12961-020-00560-6","article-title":"Exploring why global health needs are unmet by research efforts: the potential influences of geography, industry and publication incentives","volume":"18","author":"Yegros-Yegros","year":"2020","journal-title":"Health Res Policy Syst"},{"key":"10.1016\/j.bioorg.2025.109123_bb0075","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1038\/s41467-023-41194-w","article-title":"Tailored photoenzymatic systems for selective reduction of aliphatic and aromatic nitro compounds fueled by light","volume":"14","author":"Luj\u00e1n","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109123_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/cctc.202401304","article-title":"Flavin-dependent Nitroreductases: privileged enzymes for chemical and photochemical synthesis","volume":"17","author":"Russo","year":"2025","journal-title":"ChemCatChem"},{"key":"10.1016\/j.bioorg.2025.109123_bb0085","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1021\/acs.chemrestox.2c00175","article-title":"Nitroreduction: a critical metabolic pathway for drugs, environmental pollutants, and explosives","volume":"35","author":"Penning","year":"2022","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1451517","article-title":"Recent advances and applications of nitroreductase activable agents for tumor theranostic","volume":"15","author":"Shang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0095","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.pt.2014.04.004","article-title":"Policy, phylogeny, and the parasite","volume":"30","author":"Stentiford","year":"2014","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/BJ20150650","article-title":"Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility","volume":"471","author":"Williams","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2025.109123_bb0105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol."},{"issue":"2008","key":"10.1016\/j.bioorg.2025.109123_bb0110","first-page":"1392","article-title":"PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.109123_bb0115","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00731-23","article-title":"Antigiardial and antiamebic activities of fexinidazole and its metabolites: new drug leads for giardiasis and amebiasis","volume":"68","author":"Escrig","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2025.109123_bb0120","doi-asserted-by":"crossref","unstructured":"I. Rogers, K. Berg, H. Ramirez, G.A. Hovel-Miner, Fexinidazole induced cytotoxicity is distinct from related anti-trypanosome nitroaromatic drugs, (2023). doi:https:\/\/doi.org\/10.1101\/2023.10.09.561529.","DOI":"10.1101\/2023.10.09.561529"},{"key":"10.1016\/j.bioorg.2025.109123_bb0125","doi-asserted-by":"crossref","DOI":"10.1128\/jb.00326-24","article-title":"Functions of nitroreductases in mycobacterial physiology and drug susceptibility","volume":"207","author":"Eke","year":"2025","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0130","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1080\/07391102.2022.2069156","article-title":"Molecular dynamic assisted investigation on impact of mutations in deazaflavin dependent nitroreductase against pretomanid: a computational study","volume":"41","author":"Singh","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2025.109123_bb0135","doi-asserted-by":"crossref","first-page":"15203","DOI":"10.1074\/jbc.M113.547117","article-title":"Understanding the broad substrate repertoire of Nitroreductase based on its kinetic mechanism","volume":"289","author":"Pitsawong","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.701456","article-title":"Engineering the Escherichia coli Nitroreductase NfsA to create a flexible enzyme-prodrug activation system","volume":"12","author":"Sharrock","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003326","article-title":"The anti-trypanosome drug Fexinidazole shows potential for treating visceral Leishmaniasis","volume":"4","author":"Wyllie","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.109123_bb0150","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/infdis\/jis331","article-title":"Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can Arise independently in a single population","volume":"206","author":"Mejia","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bioorg.2025.109123_bb0155","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/mmi.14763","article-title":"Unraveling the antitrypanosomal mechanism of benznidazole and related 2-nitroimidazoles: from prodrug activation to DNA damage","volume":"116","author":"Dattani","year":"2021","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202401426","article-title":"Exploring multifaceted roles of Nitroreductases in bacterial, animal and plant Biosystems and their detection using fluorescent probes","volume":"9","author":"Verma","year":"2024","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2025.109123_bb0165","first-page":"391","article-title":"Engineering a multifunctional Nitroreductase for improved activation of prodrugs and PET probes for Cancer gene therapy, cell","volume":"24","author":"Copp","year":"2017","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0170","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1021\/acsinfecdis.1c00118","article-title":"From magic bullet to magic bomb: reductive bioactivation of Antiparasitic agents","volume":"7","author":"Wittlin","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bioorg.2025.109123_bb0175","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/infdis\/jiv228","article-title":"VFV as a new effective CYP51 structure-derived drug candidate for Chagas disease and visceral Leishmaniasis","volume":"212","author":"Lepesheva","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bioorg.2025.109123_bb0180","doi-asserted-by":"crossref","unstructured":"M. de N.C. Soeiro, E.M. de Souza, C.F. da Silva, D. da G.J. Batista, M.M. Batista, B.P. Pav\u00e3o, J.S. Ara\u00fajo, C.A.F. Aiub, P.B. da Silva, J. Lionel, C. Britto, K. Kim, G. Sulikowski, T.Y. Hargrove, M.R. Waterman, G.I. Lepesheva, In Vitro and In Vivo Studies of the Antiparasitic Activity of Sterol 14\u03b1-Demethylase (CYP51) Inhibitor VNI against Drug-Resistant Strains of Trypanosoma cruzi, Antimicrob Agents Chemother 57 (2013) 4151\u20134163. doi:https:\/\/doi.org\/10.1128\/AAC.00070-13.","DOI":"10.1128\/AAC.00070-13"},{"key":"10.1016\/j.bioorg.2025.109123_bb0185","doi-asserted-by":"crossref","unstructured":"E. L Maciel, J. E. Golub, J.R. Lapa e Silva, R. E. Chaisson, Tuberculosis: a deadly and neglected disease in the COVID-19 era, J. Bras. Pneumol. (2022) e20220056. doi:10.36416\/1806-3756\/e20220056.","DOI":"10.36416\/1806-3756\/e20220056"},{"key":"10.1016\/j.bioorg.2025.109123_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000027","article-title":"Comparison and lessons learned from neglected tropical diseases and tuberculosis","volume":"1","author":"Wang","year":"2021","journal-title":"PLOS Global Public Health"},{"key":"10.1016\/j.bioorg.2025.109123_bb0195","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.2174\/0929867325666180426164352","article-title":"Current and future prospects of nitro-compounds as drugs for trypanosomiasis and Leishmaniasis","volume":"26","author":"Patterson","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0205","first-page":"4629","article-title":"An overview on target-based drug design against Kinetoplastid protozoan infections: human African trypanosomiasis","volume":"26","author":"Kourbeli","year":"2021","journal-title":"Chagas Disease and Leishmaniases, Molecules"},{"key":"10.1016\/j.bioorg.2025.109123_bb0210","unstructured":"WHO, Chagas disease, WHO (2025). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chagas-disease-(american-trypanosomiasis) (accessed April 19, 2025)."},{"key":"10.1016\/j.bioorg.2025.109123_bb0215","doi-asserted-by":"crossref","first-page":"14407","DOI":"10.1038\/s41598-017-14986-6","article-title":"Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole","volume":"7","author":"Campos","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109123_bb0220","first-page":"144","article-title":"Nifurtimox nitroreductase activity in different cellular fractions from male rat pancreas","volume":"81","author":"de Mecca","year":"2007","journal-title":"Biochemical and ultrastructural alterations, Life Sci"},{"key":"10.1016\/j.bioorg.2025.109123_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2023.103485","article-title":"Dissecting the interstrand crosslink DNA repair system of Trypanosoma cruzi","volume":"125","author":"Martinez","year":"2023","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bioorg.2025.109123_bb0230","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ejmech.2018.06.040","article-title":"Current advances in drug discovery for Chagas disease","volume":"155","author":"Scarim","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0235","first-page":"25","article-title":"Diagnosis and clinical Management of Chagas Disease: an increasing challenge in non-endemic areas","volume":"13","author":"Su\u00e1rez","year":"2022","journal-title":"Res Rep Trop Med"},{"key":"10.1016\/j.bioorg.2025.109123_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00524-3","article-title":"Chad eliminates gambiense sleeping sickness","volume":"24","author":"Boisson-Walsh","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bioorg.2025.109123_bb0245","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3390\/microorganisms10071298","article-title":"Current treatments to control African trypanosomiasis and one health perspective","volume":"10","author":"Venturelli","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.bioorg.2025.109123_bb0250","first-page":"14","article-title":"The drugs of sleeping sickness: their mechanisms of action and resistance, and a brief history","volume":"5","author":"De Koning","year":"2020","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.bioorg.2025.109123_bb0255","first-page":"242","article-title":"A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis, Pathog glob","volume":"107","author":"Babokhov","year":"2013","journal-title":"Health"},{"key":"10.1016\/j.bioorg.2025.109123_bb0260","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ijbiomac.2022.09.073","article-title":"Trypanosoma cruzi nitroreductase: structural features and interaction with biological membranes","volume":"221","author":"Cirqueira","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0265","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1128\/AAC.01227-12","article-title":"Targeting the substrate preference of a type I Nitroreductase to develop Antitrypanosomal Quinone-based prodrugs","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2025.109123_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.828111","article-title":"An update on African Trypanocide pharmaceutics and resistance","volume":"9","author":"Kasozi","year":"2022","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.bioorg.2025.109123_bb0275","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1016\/j.bmcl.2011.05.009","article-title":"Synthesis and structure\u2013activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs","volume":"21","author":"Hu","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109123_bb0280","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1128\/AAC.01213-09","article-title":"Exploiting the drug-activating properties of a novel trypanosomal nitroreductase","volume":"54","author":"Hall","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2025.109123_bb0285","doi-asserted-by":"crossref","first-page":"13088","DOI":"10.1074\/jbc.M111.230847","article-title":"Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites","volume":"286","author":"Hall","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0290","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.05135-11","article-title":"Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2025.109123_bb0295","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1590\/0074-0276140497","article-title":"Megazol and its bioisostere 4h-1,2,4-triazole: comparing the trypanocidal, cytotoxic and genotoxic activities and their in vitro and in silico interactions with the Trypanosoma brucei nitroreductase enzyme","volume":"109","author":"de Carvalho","year":"2014","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.bioorg.2025.109123_bb0300","doi-asserted-by":"crossref","first-page":"8214","DOI":"10.1021\/jm201215n","article-title":"Novel 3-Nitro-1 H -1,2,4-triazole-based aliphatic and aromatic amines as anti-Chagasic agents","volume":"54","author":"Papadopoulou","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0305","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1021\/jm300508n","article-title":"Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential Antitrypanosomal agents","volume":"55","author":"Papadopoulou","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0310","first-page":"1763","article-title":"Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies, future","volume":"5","author":"Papadopoulou","year":"2013","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0315","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejmech.2014.09.045","article-title":"Novel nitro(triazole\/imidazole)-based heteroarylamides\/sulfonamides as potential antitrypanosomal agents","volume":"87","author":"Papadopoulou","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0320","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejmech.2015.08.042","article-title":"3-Nitrotriazole-based piperazides as potent antitrypanosomal agents","volume":"103","author":"Papadopoulou","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0325","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1016\/j.bmc.2015.08.014","article-title":"Discovery of potent nitrotriazole-based antitrypanosomal agents: in vitro and in vivo evaluation","volume":"23","author":"Papadopoulou","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0330","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1021\/jm5015742","article-title":"Novel 3-Nitrotriazole-based amides and Carbinols as bifunctional Antichagasic agents","volume":"58","author":"Papadopoulou","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0335","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ejmech.2016.08.002","article-title":"Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity","volume":"123","author":"Papadopoulou","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0340","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1128\/AAC.02006-15","article-title":"Evaluating 5-Nitrothiazoles as Trypanocidal agents","volume":"60","author":"O'Shea","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2025.109123_bb0345","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejmech.2018.06.001","article-title":"Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: synthesis, electrochemical and SAR study","volume":"155","author":"Pedron","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0350","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejmech.2018.07.064","article-title":"8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases","volume":"157","author":"Fersing","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112558","article-title":"8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. Brucei and cruzi","volume":"202","author":"Fersing","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0360","doi-asserted-by":"crossref","unstructured":"D.B. Carvalho, P.A.N. Costa, G.B. Portapilla, A.R. das Neves, C.Y.K. Shiguemoto, B.I. Pelizaro, F. Silva, E.M. Piranda, C.C.P. Arruda, P.D.M. Gaspari, I.A. Cardoso, P.H. Luccas, M.C. Nonato, N.P. Lopes, S. de Albuquerque, A.C.M. Baroni, Design, synthesis and antitrypanosomatid activity of 2-nitroimidazole-3,5-disubstituted isoxazole compounds based on benznidazole, Eur. J. Med. Chem. 260 (2023) 115451. doi:https:\/\/doi.org\/10.1016\/j.ejmech.2023.115451.","DOI":"10.1016\/j.ejmech.2023.115451"},{"key":"10.1016\/j.bioorg.2025.109123_bb0365","doi-asserted-by":"crossref","unstructured":"C.A.C. Menozzi, R.R.F. Fran\u00e7a, P.H. Luccas, M. dos S. Baptista, T.V.A. Fernandes, L.V.B. Hoelz, P.A. Sales Junior, S.M.F. Murta, A. Romanha, B.V.D. Galv\u00e3o, M. de O. Macedo, A. da C. Goldstein, C.F. Araujo-Lima, I. Felzenszwalb, M.C. Nonato, F.S. Castelo-Branco, N. Boechat, Anti-Trypanosoma cruzi activity, mutagenicity, Hepatocytotoxicity and Nitroreductase enzyme evaluation of 3-Nitrotriazole, 2-Nitroimidazole and Triazole derivatives, Molecules 28 (2023). doi:https:\/\/doi.org\/10.3390\/molecules28227461.","DOI":"10.3390\/molecules28227461"},{"key":"10.1016\/j.bioorg.2025.109123_bb0370","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400059","article-title":"New 2-nitroimidazole-N-acylhydrazones, analogs of benznidazole, as anti-Trypanosoma cruzi agents","volume":"357","author":"Pitombeira","year":"2024","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bioorg.2025.109123_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011107","article-title":"In vitro evaluation of new 5-Nitroindazolin-3-one derivatives as promising agents against Trypanosoma cruzi","volume":"25","author":"Pozo-Mart\u00ednez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109123_bb0380","doi-asserted-by":"crossref","unstructured":"B.I. Pelizaro, J.C.Z. Batista, G.B. Portapilla, A.R. das Neves, F. Silva, D.B. Carvalho, C.Y.K. Shiguemoto, L.R. Pessatto, E.J. Paredes-Gamero, I.A. Cardoso, P.H. Luccas, M.C. Nonato, N.P. Lopes, F. Galv\u00e3o, K.M.P. Oliveira, N.S. Cassemiro, D.B. Silva, E.M. Piranda, C.C.P. Arruda, S. de Albuquerque, A.C.M. Baroni, Design and Synthesis of Novel 3-Nitro-1 H -1,2,4-triazole-1,2,3-triazole-1,4-disubstituted Analogs as Promising Antitrypanosomatid Agents: Evaluation of In Vitro Activity against Chagas Disease and Leishmaniasis, J Med Chem 67 (2024) 2584\u20132601. doi:https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01745.","DOI":"10.1021\/acs.jmedchem.3c01745"},{"key":"10.1016\/j.bioorg.2025.109123_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107993","article-title":"Discovery of a new eugenol-benznidazole hybrid active against different evolutive stages of Trypanosoma cruzi","volume":"154","author":"de Melo","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0390","first-page":"556","article-title":"Heterologous expression and characterization of a full-length protozoan Nitroreductase from Leishmania orientalis isolate PCM2","volume":"65","author":"Pimviriyakul","year":"2023","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0395","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/labmed\/lmac134","article-title":"Review of the clinical presentation, pathology, diagnosis, and treatment of Leishmaniasis","volume":"54","author":"Mathison","year":"2023","journal-title":"Lab. Med."},{"key":"10.1016\/j.bioorg.2025.109123_bb0400","unstructured":"Leishmaniasis, (n.d.). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis (accessed April 13, 2025)."},{"key":"10.1016\/j.bioorg.2025.109123_bb0405","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bioorg.2025.109123_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006052","article-title":"Drug resistance and treatment failure in leishmaniasis: a 21st century challenge","volume":"11","author":"Ponte-Sucre","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.bioorg.2025.109123_bb0415","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2025.109123_bb0420","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bioorg.2025.109123_bb0425","doi-asserted-by":"crossref","first-page":"119re1","DOI":"10.1126\/scitranslmed.3003326","article-title":"The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis","volume":"4","author":"Wyllie","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.109123_bb0430","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/pathogens13100835","article-title":"Molecular mechanisms of drug resistance in Leishmania spp","volume":"13","author":"Moncada-Diaz","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.bioorg.2025.109123_bb0435","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00477-24","article-title":"CRISPR-Cas9 high-throughput screening to study drug resistance in Leishmania infantum","volume":"15","author":"Queffeulou","year":"2024","journal-title":"MBio"},{"key":"10.1016\/j.bioorg.2025.109123_bb0440","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/AAC.01788-12","article-title":"Assessing the essentiality of Leishmania donovani Nitroreductase and its role in nitro drug activation","volume":"57","author":"Wyllie","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2025.109123_bb0445","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1590\/0074-02760160532","article-title":"Identification of a type I nitroreductase gene in non-virulent Trypanosoma rangeli","volume":"112","author":"Montenegro","year":"2017","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.bioorg.2025.109123_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005971","article-title":"Activation of bicyclic nitro-drugs by a novel Nitroreductase (NTR2) in Leishmania","volume":"12","author":"Wyllie","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bioorg.2025.109123_bb0455","doi-asserted-by":"crossref","first-page":"28466","DOI":"10.1074\/jbc.M113.494781","article-title":"An essential type I Nitroreductase from Leishmania major can be used to activate Leishmanicidal prodrugs","volume":"288","author":"Voak","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0460","doi-asserted-by":"crossref","unstructured":"C. Fersing, L. Basmaciyan, C. Boudot, J. Pedron, S. Hutter, A. Cohen, C. Castera-Ducros, N. Primas, M. Laget, M. Casanova, S. Bourgeade-Delmas, M. Piednoel, A. Sournia-Saquet, V. Belle Mbou, B. Courtioux, \u00c9. Boutet-Robinet, M. Since, R. Milne, S. Wyllie, A.H. Fairlamb, A. Valentin, P. Rathelot, P. Verhaeghe, P. Vanelle, N. Azas, Nongenotoxic 3-Nitroimidazo[1,2- a ]pyridines Are NTR1 Substrates That Display Potent in Vitro Antileishmanial Activity, ACS Med Chem Lett 10 (2019) 34\u201339. doi:https:\/\/doi.org\/10.1021\/acsmedchemlett.8b00347.","DOI":"10.1021\/acsmedchemlett.8b00347"},{"key":"10.1016\/j.bioorg.2025.109123_bb0465","doi-asserted-by":"crossref","unstructured":"L. Navidpour, M.L. Lima, R. Milne, S. Wyllie, N. Hadj-esfandiari, M.I. Choudhary, S. Khan, S. Yousuf, Antileishmanial Activities of ( Z )-2-(Nitroimidazolylmethylene)-3(2H)-Benzofuranones: Synthesis, In Vitro Assessment, and Bioactivation by NTR 1 and 2, Antimicrob. Agents Chemother. 66 (2022). doi:https:\/\/doi.org\/10.1128\/aac.00583-22.","DOI":"10.1128\/aac.00583-22"},{"key":"10.1016\/j.bioorg.2025.109123_bb0470","unstructured":"Global tuberculosis report 2024, 1st ed, World Health Organization, Geneva, 2024."},{"key":"10.1016\/j.bioorg.2025.109123_bb0475","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/0966-842X(93)90015-J","article-title":"Tubercolosis: a neglected disease strikes back","volume":"1","author":"Kaufmann","year":"1993","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0480","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/med.20017","article-title":"Fighting tuberculosis: an old disease with new challenges","volume":"25","author":"Tripathi","year":"2005","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2025.109123_bb0485","author":"WHO"},{"key":"10.1016\/j.bioorg.2025.109123_bb0490","doi-asserted-by":"crossref","unstructured":"M. Stehr, A. A., M. Singh, Lipid inclusions in mycobacterial infections, in: Tuberculosis - Current Issues in Diagnosis and Management, InTech, 2013. doi:https:\/\/doi.org\/10.5772\/54526.","DOI":"10.5772\/54526"},{"key":"10.1016\/j.bioorg.2025.109123_bb0495","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.09-0903","article-title":"Neutrophils are the predominant infected phagocytic cells in the Airways of Patients with Active Pulmonary TB","volume":"137","author":"Eum","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.bioorg.2025.109123_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02976","article-title":"Beyond killing Mycobacterium tuberculosis: disease tolerance","volume":"9","author":"Divangahi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2025.109123_bb0505","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMcibr0902539","article-title":"The granuloma in Tuberculosis \u2014 friend or foe?","volume":"360","author":"Rubin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.109123_bb0510","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(00)03493-0","article-title":"Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection","volume":"356","author":"Hern\u00e1ndez-Pando","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2025.109123_bb0515","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/femsre\/fuz006","article-title":"Mycobacterium tuberculosis infection of host cells in space and time","volume":"43","author":"Bussi","year":"2019","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.bioorg.2025.109123_bb0520","doi-asserted-by":"crossref","unstructured":"A. S., P. C., Old and New TB Drugs: Mechanisms of Action and Resistance, in: Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance, InTech, 2012. doi:https:\/\/doi.org\/10.5772\/30992.","DOI":"10.5772\/30992"},{"key":"10.1016\/j.bioorg.2025.109123_bb0525","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3390\/app10072278","article-title":"Mycobacterial Cell Wall: a source of successful targets for old and new drugs","volume":"10","author":"Vilch\u00e8ze","year":"2020","journal-title":"Appl. Sci."},{"key":"10.1016\/j.bioorg.2025.109123_bb0530","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.str.2011.11.001","article-title":"Structure of Ddn, the Deazaflavin-dependent Nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824","volume":"20","author":"Cellitti","year":"2012","journal-title":"Structure"},{"key":"10.1016\/j.bioorg.2025.109123_bb0535","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/jm901378u","article-title":"Synthesis and structure\u2212activity relationships of Antitubercular 2-Nitroimidazooxazines bearing heterocyclic side chains","volume":"53","author":"Sutherland","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0540","author":"ClinicalTrials, A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis, ClinicalTrials"},{"key":"10.1016\/j.bioorg.2025.109123_bb0545","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0223-5234(89)90034-2","article-title":"Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with antitubercular activity","volume":"24","author":"Nagarajan","year":"1989","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2025.102630","article-title":"Functional analysis of genetic mutations in ddn and fbiA linked to delamanid resistance in rifampicin-resistant Mycobacterium tuberculosis","volume":"152","author":"Kim","year":"2025","journal-title":"Tuberculosis"},{"key":"10.1016\/j.bioorg.2025.109123_bb0555","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1021\/jm801246z","article-title":"Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4 - and 5-nitroimidazoles","volume":"52","author":"Kim","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0560","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1742-4658.2011.08404.x","article-title":"Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacteriumtuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles","volume":"279","author":"Gurumurthy","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.bioorg.2025.109123_bb0565","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1021\/acsinfecdis.7b00111","article-title":"Identification of a Mycothiol-dependent Nitroreductase from Mycobacterium tuberculosis","volume":"4","author":"Negri","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bioorg.2025.109123_bb0570","doi-asserted-by":"crossref","unstructured":"N. Gupta, V.K. Vyas, B.D. Patel, M. Ghate, Design of 2-Nitroimidazooxazine derivatives as Deazaflavin-dependent Nitroreductase (Ddn) activators as anti-mycobacterial agents based on 3D QSAR, HQSAR, and Docking Study with In Silico Prediction of Activity and Toxicity, Interdiscip Sci 11 (2019) 191\u2013205. doi:https:\/\/doi.org\/10.1007\/s12539-017-0256-1.","DOI":"10.1007\/s12539-017-0256-1"},{"key":"10.1016\/j.bioorg.2025.109123_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008287","article-title":"Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering","volume":"16","author":"Lee","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bioorg.2025.109123_bb0580","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1021\/acs.jmedchem.0c01374","article-title":"2-((3,5-Dinitrobenzyl)thio)quinazolinones: potent Antimycobacterial agents activated by Deazaflavin (F420)-dependent Nitroreductase (Ddn)","volume":"64","author":"Jian","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0585","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.1021\/acs.jmedchem.2c00972","article-title":"Nitroimidazopyrazinones with Oral activity against Tuberculosis and Chagas disease in mouse models of infection","volume":"65","author":"Ang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109123_bb0590","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300015","article-title":"Synthesis and anti-Mycobacterium tuberculosis activity of Imidazo[2,1-b][1,3]oxazine derivatives against multidrug-resistant strains","volume":"18","author":"Fernandes","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2025.109123_bb0595","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1021\/acs.jmedchem.3c00925","article-title":"Both nitro groups are essential for high Antitubercular activity of 3,5-Dinitrobenzylsulfanyl Tetrazoles and 1,3,4-Oxadiazoles through the Deazaflavin-dependent Nitroreductase activation pathway","volume":"67","author":"Karabanovich","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682501003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682501003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:00:19Z","timestamp":1777464019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682501003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":119,"alternative-id":["S004520682501003X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109123","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting nitroreductases for selective drug activation: therapeutic perspectives in neglected diseases and tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109123"}}